Safe & secure Molecules of Korolchuk IP-NFT wallet
Take control of your Molecules of Korolchuk IP-NFT assets with complete confidence in the Trezor ecosystem.
- Secured by your hardware wallet
- Use with compatible hot wallets
- Trusted by over 2 million customers
Send & receive your Molecules of Korolchuk IP-NFT with the Trezor Suite app
Send & receive
Trezor hardware wallets that support Molecules of Korolchuk IP-NFT
Sync your Trezor with wallet apps
Manage your Molecules of Korolchuk IP-NFT with your Trezor hardware wallet synced with several wallet apps.
Trezor Suite
MetaMask
Rabby
Supported Molecules of Korolchuk IP-NFT Network
- Ethereum
Why a hardware wallet?
Go offline with Trezor
- You own 100% of your coins
- Your wallet is 100% safe offline
- Your data is 100% anonymous
- Your coins aren’t tied to any company
Online exchanges
- If an exchange fails, you lose your coins
- Exchanges are targets for hackers
- Your personal data may be exposed
- You don’t truly own your coins
How to VITA-FAST on Trezor
Connect your Trezor
Open a third-party wallet app
Manage your assets
Make the most of your VITA-FAST
Trezor keeps your VITA-FAST secure
Protected by Secure ElementThe best defense against both online and offline threats
Your tokens, your controlAbsolute control of every transaction with on-device confirmation
Security starts with open-sourceTransparent wallet design makes your Trezor better and safer
Clear & simple wallet backupRecover access to your digital assets with a new backup standard
Confidence from day onePackaging & device security seals protect your Trezor’s integrity
What is the project about?
VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research.
- What is the project about?
The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose.
- What makes your project unique?
The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP.
- History of your project.
The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies.
- What’s next for your project?
The next steps involve screening third-generation compounds, conducting in vitro and in vivo models using patient